

NOVO-NORDISK AS B

ISIN: DK0060534915 WKN: - Asset Class: **Stock**

Company



2023/01/26 16:59:51

Price
939.30
DKK

Difference -0.92%(-8.70)



Contact Details

NOVO NORDISK A/S Tel: 45-44-44-88-88
 -- Fax: -
 Novo Allé 1 Web: <http://www.novonordisk.com>
 2880 Bagsværd E-mail: -

Company Profile

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2021		2020		2019	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	85,595,000,000		65,809,000,000		62,456,000,000	
Common stock capital		462,000,000		470,000,000		480,000,000
Fixed assets	108,913,000,000		79,113,000,000		63,156,000,000	
Equity capital of a company		70,746,000,000		63,325,000,000		57,593,000,000
Cash and cash equivalents	10,720,000,000		12,757,000,000		15,475,000,000	
Accrued liabilities		5,654,000,000		5,925,000,000		5,947,000,000
Other assets	-		-		-	
Current liabilities		99,516,000,000		70,273,000,000		58,983,000,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		24,246,000,000		11,324,000,000		9,036,000,000
Different income		-		-		-
Other liabilities		360,000,000		0		0
Total assets	194,508,000,000	194,508,000,000	144,922,000,000	144,922,000,000	125,612,000,000	125,612,000,000

Balance notes

	2021	2020	2019
Accounting standard	IFRS	IFRS	IFRS
Employees	47,792	45,323	43,258
Equity ratio	36.37%	43.70%	45.85%
Debt-equity ratio	174.94%	128.85%	118.10%

Others

	2021	2020	2019
Tax Expense Rate	19.16%	20.75%	19.72%

NOVO-NORDISK AS B

ISIN: DK0060534915 WKN: - Asset Class: **Stock**

Income statement

	2021	2020	2019
Turnover	140,800,000,000	126,946,000,000	122,021,000,000
Net income	47,757,000,000	42,138,000,000	38,951,000,000
EBIT	7,967,769,600	7,147,929,600	6,602,534,400
Operating income before taxes	59,104,000,000	52,981,000,000	48,690,000,000
Cash Flow	55,004,000,000	51,969,000,000	46,802,000,000
Net interest income	-180,000,000	-203,000,000	-436,000,000
Research and development expenses	16,292,000,000	13,713,000,000	12,918,000,000
Income taxes	11,323,000,000	10,992,000,000	9,602,000,000
Result from investments in subsidiaries, associates and other	-24,000,000	149,000,000	-137,000,000
Revenues per employee	395,956	376,443	379,112

Board of Directors

Helge Lund	Chairman of Supervisory Board
Martin MacKay	Member of Supervisory Board
Sylvie Grégoire	Member of Supervisory Board
Andreas Fibig	Member of Supervisory Board
Elisabeth Christensen	Member of Supervisory Board
Henrik Poulsen	Member of Supervisory Board
Jeppe Fonager Christiansen	Member of Supervisory Board
Kasim Kutay	Member of Supervisory Board
Laurence Debroux	Member of Supervisory Board
Liselotte Hyveled	Member of Supervisory Board
Mette Bøjer Jensen	Member of Supervisory Board
Thomas Rantzaau	Member of Supervisory Board

Members of Management Board

Lars Fruergaard Jørgensen	Chairman of Managing Board
Camilla Sylvest	Member of Executive Committee
Doug Langa	Member of Executive Committee
Henrik Wulff	Member of Executive Committee
Karsten Munk Knudsen	Member of Executive Committee
Ludovic Helfgott	Member of Executive Committee
Marcus Schindler	Member of Executive Committee
Martin Horst Lange	Member of Executive Committee
Maziar Mike Doustdar	Member of Executive Committee
Monique Carter	Member of Executive Committee